Overview / Abstract: |
The clinical multiple myeloma arena has undergone significant advancement in recent years; not only have 10 drugs been added to the armamentarium, but there have been important developments in diagnosis and staging, minimal residual disease (MRD) monitoring, and supportive care. The expansion of clinical options brings both opportunities and challenges for health care providers who see myeloma patients. In this roundtable, our expert panel discusses the newest evidence regarding the identification and treatment of high-risk disease, MRD measurement and results interpretation, and the clinical implications of the latest precision medicine trial results. This activity includes downloadable resources (including supplemental figures and tables). |
Expiration |
Dec 27, 2018 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Sagar Lonial, MD, FACP A. Keith Stewart, MBChB, MRCP, FRCPC, MBA Jeffrey L. Wolf, MD |
Activity Specialities / Related Topics |
Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through educational grants from Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. |
Keywords / Search Terms |
RedMedEd RedMedEd RedMedEd, MMRF, MM, multiple myeloma, risk assessment, minimal residual disease, precision medicine, oncology, hematology, Free, CME, CE, multiple myeloma patients, patient diagnosis, risk stratification, sequencing, options Free CE CME |